XSHE
000790
Market cap380mUSD
Dec 05, Last price
4.31CNY
1D
-1.15%
1Q
7.75%
Jan 2017
-53.20%
Name
Chengdu Huasun Technology Group Co Ltd
Chart & Performance
P/E
—
P/S
3.11
EPS
—
Div Yield, %
0.23%
Shrs. gr., 5y
1.65%
Rev. gr., 5y
3.00%
Revenues
864m
-13.89%
Net income
-7m
L
CFO
64m
+35.57%
Dividend
Jul 26, 20240.01 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chengdu Huasun Technology Group Inc., Ltd. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, traditional Chinese medicines, and chemical medicines; and sells drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of cardiovascular and cerebrovascular diseases. In addition, the company designs, produces, installs, and services steel structure buildings. The company was formerly known as Chengdu Taihe Health Technology Group Inc., Ltd. and changed its name to Chengdu Huasun Technology Group Inc., Ltd. in April 2020. Chengdu Huasun Technology Group Inc., Ltd. was founded in 1998 and is based in Chengdu, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||